Michael Makris: 3 PTP Haemophilia A in Japan Have Developed FVIII Inhibitors Following Treatment with Efanesoctocog Alfa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
“Three Previously Treated Haemophilia A Patients (PTPs) in Japan have developed FVIII inhibitors following treatment with efanesoctocog alfa (Altuviiio/Altuvoct). One had severe haemophilia, and the other two had moderate and mild disease. Only 38 patients were exposed to efanesoctocog alfa in the centres these 3 patients were reported from.
This is a very much higher rate than expected, and the reasons are unclear.
Was it chance? We will know very soon, as this drug is now used extensively in PTP haemophilia A patients around the world.”
Title: The First Three Japanese Haemophilia A Patients in Whom Factor VIII Inhibitors Were Observed During Prophylactic Treatment With Efanesoctocog Alfa
Authors: Tazuko Tokugawa, Akihiro Sawada, Satoshi Higasa, Mariko Asai, Hideyuki Nakazawa, Azusa Nagao, Tomoko Yamaguchi, Yushi Chikasawa, Masato Bingo, Takeshi Hagiwara, Katsuyuki Fukutake
Read more posts from Michael Makris in Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH